SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant volatility as the community debates its long-term viability amid persistent downward price action and concerns over tokenomics. While some investors are viewing the current price levels as a potential bottom for aggressive accumulation, others are expressing frustration over the lack of sustained recovery compared to the broader crypto market.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to strong quarterly growth and ongoing speculation regarding potential strategic interest or merger activity. The community is actively debating the company's valuation relative to its revenue expansion, the impact of pending litigation, and the significant institutional accumulation seen in recent filings.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased community interest driven by recent mentions in a Google research paper regarding quantum-resistant security and the network's post-quantum cryptography capabilities. While bulls are focused on accumulation and potential institutional adoption, others remain skeptical, engaging in ongoing debates about historical performance and price volatility.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) remains a focal point as traders react to persistent inflation concerns, the ongoing Iran-U.S. peace negotiations, and expectations surrounding the new Federal Reserve chair's potential policy direction. Community discourse is currently split between those anticipating a major bond market rally fueled by a potential end to geopolitical instability and others bracing for continued volatility as they monitor labor data and interest rate signals.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors focus on QNX's critical role as the foundational operating system for physical AI and robotics, a sector where the company sees significant growth potential alongside software-defined vehicles. The community is actively discussing management's shift toward high-margin subscription models, upcoming design win announcements, and the stock's positioning as an undervalued asset in the evolving autonomous technology landscape.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is currently a major focus for investors as the escalating conflict in the Middle East and the closure of the Strait of Hormuz drive significant upside for domestic oil producers. Community sentiment remains highly bullish, with many traders emphasizing the stock's strong fundamentals and high free cash flow as key pillars to withstand the market volatility surrounding potential energy supply shocks.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLA Corp is trending as investors weigh strong AI-driven infrastructure demand against sector-wide volatility triggered by semiconductor equipment peers. The community is actively discussing the company's role as an essential 'toll collector' in the chip manufacturing process while monitoring analyst price target adjustments and broader capital equipment cycles.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management systems, as well as other tools, integrations, and native payment solutions. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is experiencing high volatility as investors weigh strong quarterly earnings and aggressive share buyback plans against concerns regarding AI-driven competition and long-term sector disruption. While some market participants view the recent sell-off as an attractive value entry point, others remain cautious, debating whether AI acts as a growth accelerator for their marketing platform or a fundamental threat to the SaaS business model.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital is facing intense selling pressure as investors grapple with a significant dividend reduction and concerns over the stability of its CLO investment strategy. The community is actively debating management's decision-making and the sustainability of the fund's NAV amid a broader, volatile landscape for private credit.

TOSHI

TOSHI is trending as investors speculate on a major pivot from a meme coin to an AI utility ecosystem, with community discussions buzzing about potential token burn mechanisms and upcoming Coinbase-related announcements. Holders are actively monitoring technical indicators and social media hints, viewing current consolidation as a prime accumulation opportunity ahead of anticipated network-wide developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-acumen-pharmaceuticals-inc-stock...

Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4%

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totaling 1,545,029 shares, an increase of 46.4% from the March 31st total of 1,055,415 shares. Approximately 2.4% of the...

Acumen Pharmaceuticals (NASDAQ:ABOS) Trading 0.7% Higher   - Still a Buy?

Acumen Pharmaceuticals (NASDAQ:ABOS) Shares Up 0.7% - Here's Why...

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the stock, Marketbeat Ratings...

Acumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from BTIG Research

BTIG Research reissued a "buy" rating and issued a $8.00 target price on shares of Acumen Pharmaceuticals in a report on Thursday...

Acumen Pharmaceuticals Q4 Earnings Call Highlights

Acumen Pharmaceuticals (NASDAQ:ABOS) outlined progress across its lead Alzheimer's disease program and an emerging "enhanced brain delivery" (EBD) platform during its fourth-quarter and full-year 2025 update, while management reiterated expectations for a key Phase 2 readout later in 2026 and provid...

Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) released its earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.09...

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

Acumen Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ABOSAcumen Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABOS News